Table 4.
Determinants of lipodystrophy among HIV-infected patients in Dar es Salaam.
| Variables | AOR | 95% CI | p value |
|---|---|---|---|
| Age (years) | |||
| ≤30 | Ref | ||
| 31–40 | 0.18 | 0.05–0.65 | 0.009 |
| 41–50 | 0.59 | 0.30–1.15 | 0.120 |
| ≥51 | 1.12 | 0.58–2.19 | 0.735 |
| Gender | |||
| Female | Ref | ||
| Male | 1.66 | 1.01–2.72 | 0.045 |
| HAAT use | |||
| HAART naïve | Ref | ||
| On HAART | 13.3 | 6.4–27.7 | <0.001 |
| Type of HAART used | |||
| Nevirapine based | Ref | ||
| Efavirenz based | 0.98 | 0.36–2.66 | 0.962 |
| Stavudine based | 3.22 | 1.17–8.81 | 0.023 |
| Protease Inhibitor based | 1.06 | 0.08–9.02 | 1.00 |
| Duration of HAART use | |||
| HAART naïve | Ref | ||
| 24 months | 12.8 | 6.0–27.6 | <0.001 |
| 25–48 months | 13.6 | 5.7–32.4 | <0.001 |
| >48 months | 15.3 | 5.3–43.8 | <0.001 |
AOR: Adjusted Odds Ratio; CI: Confidence Interval; HAART: Highly Active Antiretroviral Therapy.